SEP 17, 2015 2:44 PM PDT

Less Innovation in Non-Hodgkin Lymphoma Treatment Pipeline

WRITTEN BY: Ilene Schneider
The product pipeline for Non-Hodgkin Lymphoma (NHL) exhibits a lower degree of innovation than both the industry and oncology average, with just 28 percent of all pipeline products, or 33 percent of the pipeline for which there is a disclosed molecular target, categorized as first-in-class, according to business intelligence provider GBI Research. The report said that this is in comparison to industry, breast cancer and lung cancer innovation rates of 43 percent, 57 percent and 59 percent, respectively.
There is less scope for targeted therapy for NHL. 
GBI’s latest report claims that while NHL, collectively, is the sixth to tenth most common cancer dependent on territory, each individual subtype is classified as an orphan disease. With significant differences in each subtype’s genetic profile and current treatment, there is reduced scope for the development of a targeted therapy with cross-subtype activity, explains Katie Noon, senior analyst, GBI Research, in an article in Drug Discovery & Development
 
This factor makes NHL drug development a less attractive investment than other indications in oncology, especially as survival durations across many NHL subtypes are relatively strong, and likely the reason for low first-in-class innovation levels. There is innovation in varying degrees across the majority of molecular target families and development stages for NHL therapeutics, rather than limited to a particular subset of therapies.
 
Additionally, according to the report, there is a considerable range of clinical potential across treatments with first-in-class status, especially those restricted to the early-stage NHL pipeline. Some targets, including spleen tyrosine kinase, have a great deal of supporting scientific and clinical evidence, while others have offered mixed results in preclinical studies and lack clarity on their role in disease pathophysiology.
 
GBI report also adds that despite the difficulty of several targeted NHL therapies in achieving improved efficacy rates, the development of such treatments remains of key interest across NHL. Noon says that it is hoped that one of these many targeted therapy pipeline products will repeat the success seen with rituximab, which greatly changed the NHL treatment landscape after its approval. Gaps in the treatment algorithm include “maintenance therapies to prolong initial or subsequent durations of remission, and improved therapies for relapsed patients, particularly those with a second or subsequent relapse,” the report says.
 
According to the American Cancer Society, non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts the lymphocytes, part of the body’s immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues, including the spleen and bone marrow.
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 08, 2021
Genetics & Genomics
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
JUL 08, 2021
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
Children with Down syndrome have a significantly higher likelihood myeloid leukemia occurring in the first five years of ...
AUG 01, 2021
Genetics & Genomics
Rethinking the Cause of Mutations That Lead to Melanoma
AUG 01, 2021
Rethinking the Cause of Mutations That Lead to Melanoma
Throughout our lives, new cells often replace the ones that become damaged or worn out. As cells divide, they have to re ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 06, 2021
Drug Discovery & Development
Antibiotics Increase Colon Cancer Risk by 17%
SEP 06, 2021
Antibiotics Increase Colon Cancer Risk by 17%
People who take antibiotics are at an increased risk of developing colon cancer within five to ten years. The research w ...
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
NOV 08, 2021
Cell & Molecular Biology
Understanding How Problems in Bone Marrow Transplants Arise
NOV 08, 2021
Understanding How Problems in Bone Marrow Transplants Arise
The hematopoietic system is how new blood cells are formed; hematopoietic stem cells in bone marrow generate new hematop ...
Loading Comments...